# Cel-Sci Corporation (CVM)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $97M  
**Price:** $1.18 (-9.23%)

> CEL-SCI Corporation is a biotechnology company specialized in the research and development of immunotherapy products aimed at treating cancer, autoimmune, and infectious diseases. Founded in 1983, the company focuses on activating the immune system to combat illnesses, with its flagship product, Multikine, targeting significant cancer treatment needs. CEL-SCI combines drug discovery, development, and manufacturing of complex biological substances, playing a prominent role in advancing immune-based therapeutic approaches. It serves a global healthcare market by addressing unmet medical needs through innovative immunotherapy solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2014 | $264,033 | — | -$26M | -$27M | — |
| 2013 | $159,583 | — | -$20M | -$9M | — |
| 2012 | $254,610 | — | -$17M | -$15M | — |
| 2011 | $956,154 | — | -$18M | -$26M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2014 | $19M | $9M | $11M | $9M | — |
| 2013 | $11M | $4M | $7M | $41,612 | — |
| 2012 | $16M | $9M | $7M | $4M | — |
| 2011 | $19M | $10M | $9M | $4M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$17M | $38,109 | -$17M |
| 2024 | -$19M | $94,875 | -$19M |
| 2023 | -$23M | $361,892 | -$23M |
| 2022 | -$18M | $637,892 | -$19M |
| 2021 | -$19M | $9M | -$28M |
| 2020 | -$15M | $3M | -$18M |
| 2019 | -$16M | -$177,779 | -$16M |
| 2018 | -$13M | $1,015 | -$13M |
| 2017 | -$14M | $10,525 | -$14M |
| 2016 | -$23M | $31,405 | -$23M |
| 2015 | -$24M | $73,399 | -$24M |
| 2014 | -$23M | $103,977 | -$23M |
| 2013 | -$14M | $102,033 | -$14M |
| 2012 | -$12M | $54,637 | -$12M |
| 2011 | -$23M | $216,761 | -$23M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CVM)